{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T14:36:04.888253",
  "document": "01_Article_Iptacopan C3G Trial.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 7,
  "total_validated": 7,
  "total_rejected": 0,
  "total_investigational": 5,
  "drugs": [
    {
      "matched_text": "LNP023",
      "preferred_name": "LNP023",
      "brand_name": null,
      "compound_id": "LNP023",
      "confidence": 0.8,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [],
      "context": "evere form of glomerulonephritis caused by overactivation of the alternative complement pathway. We aimed to assess efficacy and safety of iptacopan (LNP023), an oral, proximal complement inhibitor that targets factor B to selectively inhibit the alternative pathway of the complement cascade.\n\nMethods APP",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "pattern:compound_id",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "iptacopan",
      "preferred_name": "Iptacopan",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "RECRUITING",
      "sponsor": null,
      "conditions": [
        "Generalized Myasthenia Gravis"
      ],
      "nct_id": "NCT06517758",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT06517758",
          "display": null
        }
      ],
      "context": "ding Novartis Pharma.\n\nIntroduction\n\nC3 glomerulopathy is an ultra-rare and severe form of primary chronic glomerulonephritis with an estimated\n\nOral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study @k® CrossMark\n",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "corticosteroids",
      "preferred_name": "corticosteroids",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "NOT_YET_RECRUITING",
      "sponsor": null,
      "conditions": [
        "Ocular Myasthenia Gravis"
      ],
      "nct_id": "NCT06342544",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "C011244",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT06342544",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C011244",
          "display": "corticosteroid methanetriol mixture"
        }
      ],
      "context": "gible participants were randomised 1:1 via interactive response technology to either the iptacopan or the placebo group, stratified by treatment with corticosteroids, mycophenolic acid, or both (yes or no). During the 6-month double-blind period, participants orally received either iptacopan 200 mg twice daily or ",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "corticosteroid methanetriol mixture",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "mycophenolic acid",
      "preferred_name": "Mycophenolic acid",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "RECRUITING",
      "sponsor": null,
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "nct_id": "NCT02416388",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "D009173",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT02416388",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D009173",
          "display": "Mycophenolic Acid"
        }
      ],
      "context": "ase 9 (24%) 1(3%) Mixed C3 glomerulonephritis 2 (5%) 2 (6%) and dense deposit disease Unknown 1(3%) 1(3%) Corticosteroid treatment, 16 (42%) 17 (47%) mycophenolic acid treatment, or both, at time of random allocation\n\nData are n (%) unless otherwise indicated. Baseline 24-h UPCR refers to UPCR as measured by the geo",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [
        "mycophenolic acid glucuronide",
        "dextran T70-mycophenolic acid conjugate",
        "carbamoyl mycophenolic acid ethyl ester"
      ],
      "pubtator_normalized_name": "Mycophenolic Acid",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "pegcetacoplan",
      "preferred_name": "Pegcetacoplan",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.85,
      "is_investigational": true,
      "drug_class": null,
      "mechanism": null,
      "development_phase": "RECRUITING",
      "sponsor": null,
      "conditions": [
        "Fallopian Tube Carcinosarcoma",
        "Fallopian Tube Clear Cell Adenocarcinoma",
        "Fallopian Tube Endometrioid Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Ovarian Carcinosarcoma",
        "Ovarian Clear Cell Adenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Primary Peritoneal Carcinosarcoma",
        "Primary Peritoneal Clear Cell Adenocarcinoma",
        "Primary Peritoneal Endometrioid Adenocarcinoma",
        "Primary Peritoneal Serous Adenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "nct_id": "NCT04919629",
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "C000716074",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "NCT",
          "code": "NCT04919629",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C000716074",
          "display": "pegcetacoplan"
        }
      ],
      "context": "A nephropathy.’ Iptacopan became the first approved treatment for C3 glomerulopathy with approvals from both the FDA and EMA in early 2025,°” whereas pegcetacoplan (targeting C3) received approval from the FDA in July, 2025.” Based on its mechanism of action, oral iptacopan targets the underlying cause of C3 glo",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_investigational_drugs.json",
      "validation_flags": [
        "auto_validated_lexicon",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "pegcetacoplan",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "FABHALTA",
      "preferred_name": "iptacopan hydrochloride",
      "brand_name": "FABHALTA",
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": "CAPSULE",
      "route": "ORAL",
      "marketing_status": "Prescription",
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "FDA_NDA",
          "code": "NDA218276",
          "display": null
        }
      ],
      "context": "ts with C3 glomerulopathy.\" These effects persisted 9 months later, when assessed as part of the extension study.”\n\nBefore the approval of iptacopan (FABHALTA) for C3 glomerulopathy by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2025,’ there were no treatment options",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_fda_approved_drugs.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    },
    {
      "matched_text": "EMPAVELI",
      "preferred_name": "Empaveli",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "C000716074",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "2557387",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C000716074",
          "display": "pegcetacoplan"
        }
      ],
      "context": "nki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-94.\n\nAcknowledgments\n\n20 US Food and Drug Administration. EMPAVELI prescribing information. July, 2025 https://www.accessdata.fda.gov/drugsatfda_ docs/label/2025/215014sO11Ibl.pdf (accessed Aug 26, 2025).\n\nThis study",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "pegcetacoplan",
      "enrichment_source": "pubtator3"
    }
  ]
}